Health and Fitness Health and Fitness
Thu, March 26, 2009
Wed, March 25, 2009
Tue, March 24, 2009
Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009
Mon, March 16, 2009
Sun, March 15, 2009
Fri, March 13, 2009
Thu, March 12, 2009
Wed, March 11, 2009
Tue, March 10, 2009
Mon, March 9, 2009
Fri, March 6, 2009
Thu, March 5, 2009
Wed, March 4, 2009
Tue, March 3, 2009
Mon, March 2, 2009
Fri, February 27, 2009
Thu, February 26, 2009
Wed, February 25, 2009
Tue, February 24, 2009
Mon, February 23, 2009
Sun, February 22, 2009
Fri, February 20, 2009
Thu, February 19, 2009
[ Thu, Feb 19th 2009 ] - Market Wire
Enzon Reports 2008 Results
Wed, February 18, 2009

CPEX Pharmaceuticals Announces Completion of Phase 2 Trial for Urology Drug by Serenity Pharmaceuticals


//health-fitness.news-articles.net/content/2009/ .. or-urology-drug-by-serenity-pharmaceuticals.html
Published in Health and Fitness on Thursday, February 26th 2009 at 4:19 GMT, Last Modified on 2009-02-26 04:20:23 by Market Wire   Print publication without navigation


EXETER, N.H.--([ BUSINESS WIRE ])--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that its development and commercialization partner, Serenity Pharmaceuticals, has completed a Phase2a clinical study of an intranasal drug candidate delivered using CPEX's patented drug delivery platform technology for an undisclosed urology drug. During this study, 41 out of the 43 patients treated showed a positive response to treatment. Serenity has also completed an end-of-Phase-2 meeting with the FDA.

"In less than a year, our partner Serenity has taken this urology drug candidate from the Investigational New Drug application stage through an end-of-Phase-2 meeting," stated John Sedor, president and chief executive officer of CPEX Pharmaceuticals. "Serenity's continued commitment to rapid clinical development, in addition to the positive data collected in their clinical trials, make us optimistic as to the future potential of this drug candidate. In addition, this positive data, along with our ongoing progress with Nasulin™, continue to validate the significant untapped potential of CPEX's permeation enhancement technology. We look forward to providing more detail at a future date as its development continues."

About Serenity Pharmaceuticals

Serenity Pharmaceuticals is a privately held, Pennsylvania-based pharmaceutical development company.

About CPEX Pharmaceuticals

CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) is an emerging specialty pharmaceutical company focused on the development, licensing and commercialization of pharmaceutical products utilizing CPEX's validated drug delivery platform technology. CPEX has U.S. and international patents and other proprietary rights to technologies that facilitate the absorption of drugs. CPEX has licensed applications of its proprietary CPE-215® drug delivery technology to Auxilium Pharmaceuticals, Inc., which launched Testim®, a topical testosterone gel, in 2003. CPEX also is developing a proprietary intranasal insulin product candidate, Nasulin™, which is in Phase 2 clinical trials. CPEX maintains its headquarters in Exeter, NH. For more information about CPEX, please visit [ www.cpexpharm.com ].

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking statements, including, without limitation, statements regarding the prospects for development of a urology product with Serenity Pharmaceuticals and the potential of CPEX's permeation enhancement technology. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, risks associated with the following: clinical trials may not demonstrate the efficacy and safety of product candidates using CPEX's drug delivery technology, regulatory approvals may be delayed or not obtained, CPEX is dependent on other parties to conduct clinical trials and commercialize product candidates that use its drug delivery technology and such product candidates may not gain market acceptance and may not be able to compete with products of other manufacturers of proprietary pharmaceuticals, as well as risks associated with the unpredictability of patent protection, intellectual property litigation, and other uncertainties detailed under "Risk Factors" in CPEX's Registration Statement on Form 10 dated June 17, 2008 in connection with the distribution of CPEX's common stock to stockholders of Bentley Pharmaceuticals, Inc. CPEX cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and CPEX undertakes no obligation to update or revise the statements, except as may be required by law.


Publication Contributing Sources

Similar Health and Fitness Publications